Chronic liver disease

Chronic liver disease (CLD) is a progressive systemic disorder in which sustained hepatic injury produces diffuse fibrosis, regenerative nodularity, and eventual loss of synthetic and metabolic function, culminating in cirrhosis and liver failure.[1][2] It is not a jaw lesion in the odontogenic sense; its relevance to oral and maxillofacial radiology lies in the skeletal and soft-tissue consequences of impaired hepatic metabolism. The dominant etiologies are alcohol-associated liver disease, metabolic dysfunction–associated steatotic liver disease (formerly nonalcoholic fatty liver disease), and chronic viral hepatitis (B and C).[2][3]

The most reported maxillofacial imaging finding is generalized reduced bone density of the jaws (hepatic osteodystrophy), often accompanied by thinning and erosion of the mandibular inferior cortex and an increased burden of odontogenic infective radiolucencies.[4][5] Management is directed at pre-transplant dental clearance, hemostatic risk mitigation, and supporting bone health rather than at any jaw lesion itself.[5][6]

CLD denotes hepatic injury persisting beyond roughly six months along a spectrum from steatosis and chronic hepatitis through fibrosis to cirrhosis.[1][7] Cirrhosis is the histologic end stage defined by regenerative nodules surrounded by fibrous septa, clinically divided into compensated and decompensated phases. "Chronic liver failure" is used loosely as a synonym for advanced/decompensated disease and appears in the dental literature on jaw findings.[1][4][7]

• Hepatic osteodystrophy is the accepted umbrella term for the metabolic bone disease of CLD, encompassing osteopenia, osteoporosis, and (rarely) osteomalacia.[5][8]
• Metabolic dysfunction–associated steatotic liver disease (MASLD) is the current designation replacing nonalcoholic fatty liver disease.[10]
• Acute-on-chronic liver failure denotes superimposed acute decompensation with organ failure and high short-term mortality.[1]

CLD is a major global cause of morbidity and mortality; cirrhosis causes roughly 1.4 million deaths worldwide each year (Global Burden of Disease 2021).[2] In the United States the overlapping leading causes are alcohol use disorder (approximately 45% of cirrhosis), MASLD (approximately 26%), and hepatitis C (approximately 41%).[3]

• Age and sex: disease prevalence rises with age; alcohol- and viral-related disease predominate in middle-aged adults, and men are disproportionately affected. Dental cohorts of transplant candidates span a wide adult age range.[4]
• Bone involvement: osteopenia or osteoporosis is reported in up to 55% of patients with cirrhosis, and osteoporosis incidence across CLD ranges roughly 11–58%. Patients have about twice the odds of osteoporotic fracture, with fracture prevalence of 6–35%.[5][8]
• Anatomic distribution in the jaws: reduced density affects both arches and the mandibular cortex; in one case-control study, osteoporotic changes and pathologic jaw radiolucencies were markedly more frequent in chronic liver failure patients than in controls.[4]

CLD is frequently asymptomatic until decompensation; roughly 40% of patients first present with a complication.[3] Decompensating events—ascites, variceal bleeding, hepatic encephalopathy, and non-obstructive jaundice—mark a transition to high mortality, with median survival of about one year following ascites or encephalopathy.[1][3]

Orofacial and systemic findings

• Jaundice of the oral mucosa, sclerae, and skin from impaired bilirubin handling, typically evident once serum bilirubin reaches about 3 mg/dL.[11][12]
• Bleeding tendency—gingival bleeding, mucosal petechiae, ecchymoses—from deficient clotting factor synthesis, vitamin K malabsorption, and thrombocytopenia of hypersplenism.[11][12]
• Mucosal pallor, glossitis, angular cheilitis from malnutrition, anemia, and vitamin deficiencies, sometimes with superimposed candidiasis.[11][12]
• Sialosis, a bilateral painless soft parotid enlargement (classically in alcohol-associated liver disease), and sicca symptoms (particularly with HCV infection and primary biliary cholangitis).[12]
• Periodontitis and poor oral hygiene are highly prevalent and associated with worse nutritional status, systemic inflammation, and higher cirrhosis-related mortality.[10][13][14]

Tempo and red flags

Progression ranges from weeks in biliary obstruction to decades in chronic viral hepatitis.[1] Red flags for the dental team include new jaundice, spontaneous gingival hemorrhage, fetor hepaticus or encephalopathy, and acute dentoalveolar infection in a transplant candidate.[6][12]

The jaw manifestations are those of a generalized metabolic bone disorder superimposed on heightened odontogenic infection, rather than a discrete expansile lesion. Findings are best appreciated on panoramic imaging, which performs as a cost-effective opportunistic screen for these changes.[4]

Location and distribution

Changes are diffuse and bilateral, involving the alveolar processes of both jaws and the basal mandible rather than being focal.[4] Superimposed focal radiolucencies are distributed about the teeth, reflecting their odontogenic infective origin.[4]

Internal architecture

• Generalized osteopenia with a rarefied, sparse trabecular pattern and reduced radiographic contrast between bone and soft tissue is the core finding; in one case-control study, osteoporosis was detected in roughly one-third of chronic liver failure patients and was about 20 times more likely than in controls.[4]
• Idiopathic osteosclerosis (focal radiopaque bone) was also more prevalent in that study.[4]

Effects on teeth and adjacent structures

• Pathologic periapical and inflammatory radiolucencies were about 9 times more frequent than in controls in the same study, arising from untreated caries and periodontitis; dental caries prevalence exceeds 70% in pre-transplant patients, with xerostomia-related cervical caries in cholestatic disease and HCV.[4][5][15]
• Alveolar bone loss from concurrent periodontitis, and widespread calculus, are common.[5][14]

Cortical involvement

• Thinning of the inferior mandibular cortex is characteristic; reduced mandibular cortical width correlates with low systemic bone mineral density.[4][16]
• Cortical erosion graded by the mandibular cortical index—from a smooth sharp endosteal margin (C1), through semilunar/lacunar endosteal defects (C2), to a heavily porous residual cortex (C3)—tracks with reduced density, with C3 and cortical width of 3 mm or less favoring osteoporosis. The panoramic mandibular index (cortical width relative to the mental foramen–to–inferior border distance, cutoff near 0.3) is the companion quantitative measure.[16][17][18][19]

Associated and variant findings

• Condylar degenerative change was significantly more common in that study.[4]
• Tonsilloliths and other soft-tissue calcifications were also more frequent in that study.[4]
• Note that densitometric correlation is less reliable in patients with ascites, where fluid superimposition degrades axial bone density measurement—an incentive to use jaw indices opportunistically.[4]

The pattern that prompts a differential is generalized reduced jaw density with a thinned, eroded mandibular cortex, plus multiple inflammatory radiolucencies—features that are not specific to CLD and overlap with other causes of secondary osteopenia and demineralization. Liver-specific history and laboratory data are the decisive discriminators.[8]

The highest-risk pitfall is attributing every jaw radiolucency to benign hepatic osteodystrophy and overlooking an active odontogenic focus in a transplant candidate, where infection materially affects graft outcomes. Correlate each lucency with the adjacent tooth and pulp status; obtain PTH, calcium, phosphate, renal function, 25-hydroxyvitamin D, a coagulation panel, and platelet count, and biopsy any lesion with lesion-like corticated margins or atypical multiplicity.[5]

The defining pathology is hepatic: progressive fibrosis replacing normal architecture with regenerative parenchymal nodules surrounded by fibrous septa, the histologic substrate of cirrhosis.[1][7] The maxillofacial correlates are secondary.

• Bone: hepatic osteodystrophy in cholestatic disease and cirrhosis reflects predominantly reduced bone formation, with osteoblast proliferation suppressed in a dose-dependent fashion by elevated bilirubin, compounded by impaired hepatic hydroxylation of vitamin D, secondary hyperparathyroidism, hypogonadism, vitamin K deficiency, and low IGF-1. In other CLD etiologies, chronic inflammation, direct toxicity, and increased resorption contribute. Radiologic–pathologic correlation: the rarefied trabeculae and eroded cortex on panoramic imaging mirror this low-turnover, under-mineralized state.[4][8]
• Salivary gland: sialosis shows bland acinar hypertrophy; HCV-associated sicca shows periductal lymphocytic infiltration with sparing of ducts, distinguishing it from Sjögren syndrome.[12]
• Mucosa/periodontium: cirrhosis is associated with a distinctive subgingival dysbiosis in which classic red-complex periodontal pathogens are relatively less abundant, reflecting the immunocompromised host milieu.[14]

Management in the oral and maxillofacial setting centers on pre-transplant dental clearance, hemostatic planning, and bone-health support, coordinated with hepatology.[5][6]

Workup and referral

• Eliminate foci of infection—caries, periodontitis, calculus, and non-restorable teeth—before transplantation, as dental disease raises peri-transplant bacterial infection risk. In high-MELD or high-bleeding-risk patients, defer elective procedures until after transplant; treat only acute dentoalveolar infection or aspiration risk pre-operatively.[5][6]
• Assess vitamin D and bone density during transplant evaluation, with calcium and vitamin D supplementation, weight-bearing exercise, and alcohol/tobacco cessation as first-line measures.[4][5]

Hemostasis and drug handling

• Bleeding is the principal procedural risk but is unpredictable and poorly predicted by INR or platelet count; it occurs in less than 10% of extractions and is usually controlled by local measures. Platelet thresholds of about 50,000–60,000/µL are commonly cited for higher-risk procedures, and TPO-receptor agonists (avatrombopag, lusutrombopag) or antifibrinolytics such as tranexamic acid are options.[5][6][21]
• Impaired hepatic drug metabolism and hypoalbuminemia alter the effect of analgesics, sedatives, and antibiotics. Avoid NSAIDs; acetaminophen is the preferred analgesic at a reduced dose (generally no more than 2 g/day); metronidazole, benzodiazepines, and opioids require dose reduction or avoidance.[12]

Bone-directed therapy and prognosis

• Bisphosphonates have not consistently improved bone density or fractures in primary biliary cholangitis and are of uncertain benefit in other etiologies, though they appear safe in cirrhosis including those with varices; reserve for selected higher-risk patients.[5]
• Bone density falls further in the first 3–6 months after transplant, with incident fractures in up to 20% of recipients, so pre-transplant bone status is prognostically important.[5][8]
• Overall prognosis follows the underlying liver disease: decompensation sharply raises mortality, roughly 1–4% of cirrhotic patients develop hepatocellular carcinoma annually, and transplantation is the definitive treatment for end-stage disease.[1][2][3]

Pediatric disease

In children and adolescents with CLD, oral candidiasis, telangiectasia, atrophic ("bald") tongue, cracked lips, yellow-brown gingival discoloration, petechiae, and gingival bleeding correlate with the severity of liver dysfunction, coagulopathy, hyperbilirubinemia, and portal hypertension, and can signal disease progression.[22]

Oral lichen planus and malignant risk

CLD—particularly chronic HCV infection—is reproducibly associated with oral lichen planus (odds ratios roughly 3–6), with pooled cirrhosis prevalence near 4% in affected patients.[23][24][25] Because oral lichen planus carries malignant potential and these patients already face elevated hepatocellular carcinoma risk, mucosal surveillance and hepatic screening are warranted when either condition is identified.[24]